Can sustained GABA-A sedative use make abrupt withdrawal cause temporary hyperexcitability?

Sustained use of GABA-A receptor–acting sedatives, especially benzodiazepines, can produce neuroadaptations that make abrupt cessation clinically hazardous. The core claim is supported: reduced inhibitory signaling and compensatory excitatory processes provide a biologically coherent basis for transient withdrawal-related CNS hyperexcitability.

Neurobiological evidence

• Animal and in-vitro lorazepam studies show reduced benzodiazepine-site/GABA-channel coupling and lower maximal GABA-dependent chloride uptake in cortex and hippocampus after 7 days, consistent with diminished functional GABA-A–mediated inhibition.
• Longer lorazepam exposure reduced cortical α1 and γ2 GABA-A receptor-subunit mRNA, illustrating region- and subtype-specific receptor adaptation rather than uniform receptor loss.
• Compensatory excitation is also implicated: NMDA-receptor antagonism prevented lorazepam anticonvulsant tolerance despite comparable GABA-A receptor downregulation, indicating that glutamatergic/NMDA-mediated drive contributes beyond inhibitory-receptor adaptation alone.
• Continuous zolpidem exposure has been associated with GABA/benzodiazepine-site uncoupling, but evidence for excitatory adaptation is much stronger for benzodiazepines.

Clinical significance and safety

• In physically dependent benzodiazepine users, abrupt cessation can precipitate agitation, autonomic instability, delirium, and seizures—clinical expressions of a temporary hyperexcitable CNS state. ASAM identifies seizures and delirium as potentially life-threatening consequences of rapid reduction or abrupt discontinuation.
• For zolpidem and related Z-drugs, reports of seizures and delirium after abrupt cessation mainly involve prolonged or supratherapeutic use; they support biological plausibility but do not quantify risk at usual therapeutic doses.
• At age 77, severe withdrawal manifestations such as delirium or seizures are particularly consequential. Abrupt stopping after sustained regular use should be avoided; gradual, individualized tapering and seizure-risk assessment are the safer clinical approach, with monitored care when delirium, unstable vital signs, or significant comorbidity is present.

Bottom line

• The claim is well supported clinically for withdrawal hyperexcitability and moderately supported mechanistically: chronic GABA-A sedative exposure can reduce inhibitory responsiveness and engage excitatory compensation, so abrupt removal—particularly after benzodiazepine dependence—can cause dangerous but typically transient CNS overactivity.